program logo/macu/on light

Applications Now Open for BrightFocus Macular Degeneration Research Grants

  • Press Release
Published on:
A photo of a retina with the following text: Apply for a Macular Degeneration Research Grant

Research Awards to Fund Innovative Vision Science

Clarksburg, MD—BrightFocus Foundation, a premier private funder of vision research, today announced a request for proposals for projects supported through its Macular Degeneration Research program. The deadline for Letters of Intent is July 29, 2021 for projects beginning in 2022.

The grants cover a wide range of investigator-initiated topics to better understand, treat, and prevent age-related macular degeneration, a leading cause of blindness. With a strong emphasis on early career scientists and their new ideas, BrightFocus offers three levels of grants:

  • Postdoctoral Fellowship (maximum award value $200,000, 2 years)
  • New Investigator Grant (maximum award value $450,000, up to 3 years)
  • Innovative Research Grant (maximum award value $600,000, up to 3 years)

BrightFocus funding has blazed new trails of discovery, including breakthroughs that have led to multiple Nobel Prizes. “We encourage scientists from around the world to bring us their bold, high-impact ideas, the ‘what-if’s’ of science that may someday help save sight,” said Diane Bovenkamp, PhD, BrightFocus Vice President for Scientific Affairs.

Visit here for more information about the BrightFocus macular degeneration grants, including how to apply. Our most recent yearbook gives an overview of scientific projects the program is currently supporting around the globe.

About BrightFocus

BrightFocus Foundation is a premier source of private research funding to defeat Alzheimer’s, macular degeneration, and glaucoma. The organization has supported over 275 projects, a $60 million investment, over the past three years alone to find the cures for diseases of mind and sight. It shares the latest research findings and best practices to empower families impacted by these diseases.